Group 1 - Robbins LLP is investigating BellRing Brands, Inc. for potential violations of securities laws and breaches of fiduciary duties by certain officers and directors [1] - BellRing Brands manufactures and sells nutrition products both in the U.S. and internationally [1] - Shareholders who have lost money in their investment in BellRing Brands are encouraged to contact Robbins LLP for more information about their rights [1] Group 2 - Robbins LLP operates on a contingency fee basis, meaning shareholders pay no fees or expenses [2] - The firm has been dedicated to helping shareholders recover losses and improve corporate governance since 2002, having obtained over $1 billion for shareholders [2] Group 3 - Shareholders can sign up for alerts regarding class action settlements or corporate executive wrongdoing related to BellRing Brands [3]

DENVER, July 10, 2025 (GLOBE NEWSWIRE) -- The Simply Good Foods Company (Nasdaq: SMPL) (“Simply Good Foods,” or the “Company”), a developer, marketer and seller of branded nutritional foods and snacking products, today reported financial results for the thirteen and thirty-nine weeks ended May 31, 2025. The acquisition of Only What You Need, Inc. ("OWYN") was completed on June 13, 2024. Therefore, the Company's year-ago performance for the thirteen and thirty-nine weeks ended May 25, 2024, does not include ...

Los Angeles, CA , July 07, 2025 (GLOBE NEWSWIRE) -- Luma Nutrition is proud to announce that its flagship product, Luma Nutrition Magnesium Glycinate 1000mg, has officially surpassed 10,000 units sold per month on Amazon. As one of the best magnesium glycinate supplements available in 2025, this high-absorption formula continues to earn praise for its purity, effectiveness, and ability to support restful sleep, mental clarity, and full-body relaxation.  The milestone underscores growing consumer demand for ...

Company Overview - BellRing Brands, Inc. is a consumer nutrition company that produces and sells ready-to-drink protein shakes, powders, bars, and other nutrition products under brands such as Premier Protein, Dymatize, and PowerBar [3]. Allegations of Wrongdoing - On May 6, 2025, BellRing disclosed during its quarterly earnings call that it anticipated a reduction in retailer inventory levels for the third quarter of 2025. The company projected "Q3 net sales growth of low-single-digits with Premier Protein the main driver and all others flat to down" [4]. - Following this announcement, BellRing's stock price experienced a significant decline, falling by $14.88 per share, or 18.97%, to close at $63.55 per share on the same day [4]. Legal Investigation - Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving BellRing, stemming from allegations of providing misleading business information to the investing public [1].

Core Insights - The article discusses recent developments in the nutrition and health industry, highlighting regulatory changes, new product approvals, and market trends that could impact investment opportunities [2][3][4][5][6]. Regulatory Developments - The State Administration for Market Regulation issued a guideline clarifying the definition of commercial advertising under the Advertising Law, addressing ongoing disputes in advertising enforcement [2]. - The National Health Commission approved D-alloheptulose and four other substances as new food raw materials, indicating a push for innovation in the nutrition sector [3]. - The market regulator released multiple responses to proposals regarding health food regulations, signaling a focus on traditional Chinese medicine formulations as a potential growth area [4]. Market Trends and Investment Opportunities - Yangtuo Technology Inc. submitted an IPO application to the Hong Kong Stock Exchange, aiming to raise funds for market expansion and supply chain optimization, reflecting growing investor interest in the nutrition and health sector [5]. - A report on 68 nutrition and health companies showed an average market value increase of 20% in the first half of the year, driven by rising consumer health awareness and demand for nutritional products [6]. Company Performance - New Hope Liuhe (002001) projected a net profit of 3.3 billion to 3.75 billion yuan for the first half of 2025, representing a year-on-year growth of 50% to 70% [12]. - Brother Technology (002562) expects a net profit of 60 million to 75 million yuan for the same period, marking an increase of 325% to 431% compared to the previous year [13]. New Product Launches - Guangji Pharmaceutical (000952) received a notice of administrative penalty for information disclosure violations, indicating regulatory scrutiny in the sector [14]. - TCM brand Tongrentang launched its first OTC glucosamine product, expanding its product line in the bone and joint health category [14].

Core Viewpoint - The healthcare sector is positioned as a strong long-term investment opportunity, with a focus on companies that have shown adaptability and are well-prepared for future challenges [2]. Group 1: Abbott Laboratories - Abbott Laboratories, founded in 1888, has a market capitalization of $240 billion and offers diverse healthcare products across multiple sectors [4]. - The company is a leader in medical devices, diagnostics, nutritional products, and established pharmaceuticals, with notable products like the MitraClip and FreeStyle Libre [5][6]. - Abbott anticipates an 8% year-over-year revenue growth in 2025 and continues to innovate, recently receiving the European CE Mark for the Volt PFA System [7][8]. - Abbott has a strong dividend history, having increased its dividend for 53 consecutive years [8]. Group 2: AbbVie - AbbVie, spun off from Abbott in 2013, has a market capitalization of approximately $328 billion and generated $56.3 billion in sales last year [9][10]. - The company has successfully navigated the loss of U.S. exclusivity for its top product, Humira, by investing in R&D and acquisitions, leading to a robust product pipeline [11]. - AbbVie’s successors to Humira, Rinvoq and Skyrizi, are projected to generate combined sales of $31 billion by 2027, surpassing Humira's peak sales [12]. - AbbVie has increased its dividend by a cumulative 310% since its spin-off, with a forward dividend yield of 3.51% [12]. - The stock is considered relatively inexpensive, trading at 15.2 times forward earnings, with growth potential from new products [13].

Core Viewpoint - Nature's Sunshine Products, Inc. is conducting a secondary public offering of up to 2,854,607 shares at a price of $12.00 per share, with the offering expected to close on June 27, 2025 [1][2]. Group 1: Offering Details - The Selling Stockholder, Fosun Pharma USA, Inc., will receive all net proceeds from the offering, while Nature's Sunshine will not sell any shares or receive any proceeds [2]. - The Company has agreed to potentially purchase up to $15.0 million of its common stock from the underwriters as part of its share repurchase program, but there is no guarantee that any shares will be purchased [3]. - D.A. Davidson & Co. is acting as the sole book-running manager for the offering, which is made under a shelf registration statement filed with the SEC [4]. Group 2: Company Background - Nature's Sunshine Products is a leading manufacturer of herbal and nutritional supplements, distributing products in over 40 countries and ensuring high quality through its own manufacturing facilities [8].

Core Viewpoint - Nature's Sunshine Products, Inc. is launching a secondary public offering of up to 2,854,607 shares of its common stock, which will be sold by Fosun Pharma USA, Inc. as the selling stockholder [1][2]. Group 1: Offering Details - The selling stockholder will receive all net proceeds from the offering, while Nature's Sunshine will not sell any shares or receive any proceeds [2]. - The company has agreed to potentially purchase up to $15.0 million of its common stock from the underwriters as part of its share repurchase program, but there is no guarantee that any shares will be purchased [3]. - D.A. Davidson & Co. is acting as the sole book-running manager for the offering, which is being conducted under a shelf registration statement filed with the SEC [4]. Group 2: Company Background - Nature's Sunshine Products is a leading manufacturer of herbal and nutritional supplements, marketing products in over 40 countries and ensuring high quality through its own manufacturing facilities [8].

Core Viewpoint - USANA Health Sciences (USNA) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on an upward trend in earnings estimates, which significantly influences stock prices [1][4]. Earnings Estimates and Stock Ratings - The Zacks rating system is primarily driven by changes in a company's earnings picture, with the Zacks Consensus Estimate tracking EPS estimates from sell-side analysts [2]. - The correlation between earnings estimate revisions and near-term stock price movements makes the Zacks rating system valuable for investors, as it provides a clearer picture than subjective Wall Street analyst ratings [3][7]. Institutional Investor Influence - Institutional investors play a role in the relationship between earnings estimates and stock prices, as they adjust their valuations based on these estimates, leading to significant stock transactions that affect price movements [5]. Business Improvement Indicators - Rising earnings estimates and the Zacks rating upgrade for USANA Health suggest an improvement in the company's underlying business, which could lead to increased stock prices as investors respond positively [6]. Earnings Estimate Revisions for USANA Health - For the fiscal year ending December 2025, USANA Health is expected to earn $2.61 per share, with no year-over-year change, but the Zacks Consensus Estimate has increased by 1.8% over the past three months [9]. Zacks Rank System Performance - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [8]. - The upgrade of USANA Health to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating strong potential for market-beating returns in the near term [11].

Key Takeaways Five stocks were screened for low P/B ratios, solid value scores, and strong projected EPS growth. STNE shows the highest 3-5 year EPS growth rate at 26.3%, followed by PSFE at 17.9% and USNA. All selected stocks have a Zacks Rank of 1 or 2 and meet key valuation, liquidity, and pricing criteria.Value investing offers an opportunity to enter the market and grab stocks that have otherwise been overlooked by the majority of investors and are thus trading at cheap multiples.Though price to earn ...